CClinicalTrials.gg
Sign In
CompletedNCT03852862DRAVATSUpdated Apr 17, 2026

Double Regional Anesthesia in Video Assisted Thoracoscopy

A Phase 4 interventional study of Serratus plane block and paravertebral block and paravertebral block in Video Assisted Thoracoscopy and Anesthesia, sponsored by University Hospital, Rouen. Completed at 1 site in France. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-04-17.

Sponsored by University Hospital, Rouen · Phase 4, Interventional, and Treatment

Phase
Phase 4
Study type
Interventional
Enrollment
112
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

Monocentric, randomized, controlled, single-blind study who's aim is to demonstrate the efficacy of the association of paravertebral block and serratus plane block with paravertebral block alone

02

Conditions studied

  • Video Assisted Thoracoscopy
  • Anesthesia
03

In context

Lead sponsor

University Hospital, Rouen is the lead sponsor of 410 studies on the registry; 104 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Patient aged 18 to 75 years;
  • Programmed for unilateral videothoracoscopy for anatomical resection (segmentectomy, lobectomy);
  • Subject affiliated to a social security scheme;
  • Subject having signed an informed consent

Exclusion criteria

Exclusion Criteria:

  • Chronic treatment with opiates;
  • Contraindication to administration of morphine;
  • Allergy to local anesthetics or contraindications to the use of ropivacaine;
  • Contraindication to the realization of paravertebral blocks and serratus;
  • Pregnancy, breastfeeding;
  • Severe obesity (BMI > 40 kg/m²);
  • Renal impairment (GFR \< 30 mL/min) or known severe hepatic impairment;
  • Difficulties of comprehension preventing the collection of consent and the realization of the study;
05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
112 participants (actual)

Study arms

  • Experimental
    Serratus plane block with paravertebral block

    Association of Serratus plane block and paravertebral block for anesthesia

    Drug: Serratus plane block and paravertebral block

  • Active comparator
    paravertebral block alone

    Paravertebral block for anesthesia

    Drug: paravertebral block

Interventions

  • DrugSerratus plane block and paravertebral block

    Single Administration of 20 mL of ropivacaine for Serratus plane block (Intra-muscular injection) followed by a single administration of 20 ml ropivacaine for paravertebral block (T4 inter-vertebral injection)

  • Drugparavertebral block

    Single Administration of 20 ml of ropivacaine for paravertebral block (T4 inter-vertebral injection)

06

What researchers measure

Primary outcomes

  1. Number of opioids drug administrated

    Time frame: 24 hours postoperatively

Secondary outcomes

  1. Length of stay in recovery room

    Time frame: 24 hours postoperatively

  2. Total duration of hospitalization

    Time frame: during the 28 days postoperatively

07

Study locations

1 site
  • Rouen University Hospital
    Rouen, France
08

References and documents

Publications

  • Dusseaux MM, Grego V, Baste JM, Besnier E, Boujibar F, Koscianski G, Ben Yahia MM, Compere V, Clavier T, Vannier M, Selim J. Paravertebral block combined with serratus anterior plane block after video-assisted thoracic surgery: a prospective randomized controlled trial. Eur J Cardiothorac Surg. 2023 Jul 3;64(1):ezad170. doi: 10.1093/ejcts/ezad170. PubMed 37094177 ↗
09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Apr 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03852862
Lead sponsor
University Hospital, Rouen
Responsible party
Sponsor
First posted
Feb 25, 2019
Start date
May 8, 2019
Primary completion
Nov 10, 2020
Completion
Nov 10, 2020
Last update
Apr 17, 2026

Study contacts

Marie-Melody DUSSEAUX, MD
principal investigator · University Hospital, Rouen

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies from this sponsor

University Hospital, Rouen

Start the discussion